Evaluation of the prevalence of metachronous second primary malignancies in hypopharyngeal carcinoma and their effect on outcomes.
Cancer Med
; 11(4): 1059-1067, 2022 02.
Article
en En
| MEDLINE
| ID: mdl-35080148
ABSTRACT
BACKGROUND:
To investigate the clinical characteristics of metachronous second primary malignancies (Met-SPMs) and its impact on prognosis in hypopharyngeal carcinoma (HPC).METHODS:
We reviewed 593 newly diagnosed HPC patients without invasive synchronous SPMs (Syn-SPMs) who were treated in our cancer center between 2009 and 2019. According to the status during follow-up, patients were classified into three groups (a) without SPMs (No-SPMs, n = 440), (b) with tumors in situ in the esophagus or stomach (Tis, n = 80), or (c) with Met-SPMs (n = 73).RESULTS:
The median follow-up time for entire cohort (n = 593) was 66.7 months. Met-SPMs were present in 12.3% of the cohort (73/593). The predominant site of SPMs was esophagus, followed by lung, oral cavity, thyroid, stomach, and oropharynx. In Met-SPMs group, both index tumor and SPMs were the main causes of death. Tis group exhibited comparable 5-year overall survival (OS) and disease-specific survival (DSS) with that of No-SPMs group. The Met-SPMs group had similar 5-year OS rate and better 5-year DSS rate of 47.3% versus 43.6% (odds ratio [OR], 0.931; 95% confidence interval [CI], 0.681-1.274, p = 0.657) and 66.3% vs. 46.2% (OR, 0.600; 95% CI, 0.402-0.896, p = 0.012), respectively, compared with the No-SPMs group.CONCLUSION:
The overall incidence of Met-SPMs in HPC was 12.3%. The occurrence of Met-SPMs does not jeopardize the survival outcome of HPC. Routine surveillance of Met-SPMs was requisite for patients with HPC.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Carcinoma de Células Escamosas
/
Neoplasias Hipofaríngeas
/
Neoplasias Primarias Secundarias
Tipo de estudio:
Etiology_studies
/
Observational_studies
/
Prevalence_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Cancer Med
Año:
2022
Tipo del documento:
Article
País de afiliación:
China